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The in vitro activity of a new orally administered carbacephem analog of cefaclor, loracarbef (LY163892),
was compared with those of cefaclor and several other oral antimicrobial agents against recent clinical isolates
of Haemophilus influenzae and Moraxella catarrhalis. Loracarbef was found to be slightly more active than
cefaclor against H. influenzae and had activity essentially equivalent to that of cefaclor for M. catarrhalis.
Resistance to loracarbef was uncommon and was noted only with rare ,l-lactamase-producing strains of H.
influenzae. On the basis of these observations, loracarbef may be of utility in the management of localized,
non-life-threatening infections caused by H. influenzae and M. catarrhalis.
Loracarbef (LY163892) is a new orally administered car-
bacephem class antimicrobial agent in which the sulfur atom
of the dihydrothiazine ring of cefaclor has been replaced
with a carbon atom. The result of this substitution is that
loracarbef is more stable in serum than is cefaclor. Loracar-
bef is the first carbacephem class beta-lactam antimicrobial
agent to undergo clinical development. Its chemical name is
(6R,7S)-7-[(R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-
1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid monohy-
drate (C1604N3H16Cl H20). The molecular weight of lora-
carbef is 367.8.
Since loracarbef will be marketed as an oral agent for
use in the management of respiratory tract infections such
as acute otitis media, sinusitis, and bacterial bronchopul-
monary infections (10a), and since, as a beta-lactam anti-
microbial agent, its activity against 3-lactamase-producing
organisms is of concern, the in vitro activity of loracarbef
was assessed against Haemophilus influenzae and Moraxella
catarrhalis, two frequent causes of these infections which
often produce ,-lactamase. The in vitro activity of lora-
carbef was compared with those of several other com-
monly used oral antimicrobial agents: ampicillin, amoxicil-
lin-clavulanate, cefaclor, cefuroxime, cefixime, trimetho-
prim-sulfamethoxazole, erythromycin, and the combination
erythromycin-sulfisoxazole. In addition, cephalothin, chlor-
amphenicol, and sulfisoxazole (alone) were also tested.
A total of 307 clinical isolates of H. influenzae and 146
clinical isolates of M. catarrhalis were examined. Isolates
were obtained from patients in the United States who were
enrolled in multicenter clinical trials of loracarbef during
1989. The disease associations of the isolates and the number
of study centers contributing strains are listed in Table 1. In
patients with otitis media, isolates were recovered from
tympanocentesis fluid. Sinus aspirates were the source of
isolates from patients with acute maxillary sinusitis. In
patients with acute bronchitis, acute purulent exacerbation
of chronic bronchitis, or pneumonia, isolates were usually
obtained from expectorated sputa that had been judged to be
satisfactory on the basis of Gram-stained smears. All sus-
* Corresponding author.
ceptibility testing was performed in one laboratory (Univer-
sity of Massachusetts Medical Center).
A broth microdilution MIC procedure was used to deter-
mine the MICs of 12 antimicrobial agents (3, 10). A final
volume of 100 ,u per well was used with a final inoculum size
of ca. 5 x 105 CFU/ml. Microdilution trays were incubated
for 22 to 24 h at 35°C in ambient air prior to determination of
MICs. Haemophilus Test Medium broth prepared in-house
was used for MIC determinations with both H. influenzae
and M. catarrhalis (7). Extensive preliminary studies dem-
onstrated concordance between microdilution MIC results
obtained with M. catarrhalis when it was tested in Hae-
mophilus Test Medium broth versus those when it was
tested in cation-adjusted Mueller-Hinton broth (unpublished
data).
The antimicrobial agents tested in this study were ob-
tained from their respective manufacturers as reagent-grade
powders. These included ampicillin (Bristol-Myers); amoxi-
cillin-clavulanate (Smith-Kline Beecham); cephalothin, ce-
faclor, and loracarbef (Lilly); cefuroxime (Glaxo); cefixime
(Lederle); chloramphenicol (Parke-Davis); trimethoprim and
sulfamethoxazole (Hoffmann-LaRoche); and erythromycin
(Abbott). The range of concentrations tested for each anti-
microbial agent was such that most test strains yielded
on-range MIC values, i.e., defined MICs rather than values
less than or greater than the specific concentrations tested.
Five strains of H. influenzae, including ATCC 49247 and
ATCC 10211, were used as daily controls. Three strains of
M. catarrhalis, all previously extensively characterized in
our laboratory, were also used as daily controls. P-Lacta-
mase production was assessed with all study isolates by use
of a chromogenic cephalosporin assay (9) which used nitro-
cefin-impregnated filter paper disks (cefinase disks; Becton-
Dickinson Microbiology Systems, Cockeysville, Md.).
All MIC determinations were performed twice on different
days, and the results were averaged to achieve an assigned
MIC for a given organism-antimicrobial agent combination.
When duplicate MICs varied by one twofold concentration
increment, the higher MIC was taken as the assigned MIC.
Among a total of 3,684 duplicate MIC determinations with
H. influenzae, the two results were the same or varied by
one or two twofold concentration increments in 3,448 (94%),
1504
VOL. 35, 1991
TABLE 1. Description of sources of clinical isolates of
H. influenzae and M. catarrhalis
No. of Disease No. of strains of:
study ting association H. influenzae M. catarrhalis
15 Acute otitis media 105 (36, 34) 59 (54, 91)
4 Acute maxillary sinusitis 17 (3, 18) 3 (3, 100)
74 Bronchitis 147 (28, 19) 84 (57, 68)
6 Pneumonia 38 (5, 13) 0
Total 307 (72, 23) 146 (114, 78)
a Numbers in parentheses refer to the number, percentage of strains that
were P-lactamase positive.
202 (5%), and 34 (0.9%) cases, respectively. With M. ca-
tarrhalis (1,752 duplicate MIC determinations), the following
was observed: no difference, 1,677 cases (96%); a difference
of one dilution, 62 cases (3%); and a difference of two
dilutions, 13 cases (0.7%).
As seen in Table 2, loracarbef was active against both
,-lactamase-positive and -negative strains of H. influenzae.
The geometric mean loracarbef MICs for P-lactamase-posi-
tive and -negative strains of H. influenzae were 1.4 and 2.0
,ug/ml, respectively. If a loracarbef MIC of .8.0 ,ug/ml was
used to define strains of H. influenzae as being susceptible,
87 and 95% of ,B-lactamase-positive and -negative strains,
respectively, were found to be loracarbef susceptible. Use of
an MIC of .8.0 ,ug/ml to define the susceptible category with
loracarbef seems appropriate, insofar as this same criterion
has been applied to cefaclor when tested against H. influ-
enzae (10). Furthermore, peak achievable levels of loracar-
bef in plasma are typically ca. twofold higher than this
breakpoint when the drug is administered orally in standard
doses (i.e., 200 mg) (8). Of 73 ,B-lactamase-positive strains,
for 4 strains (6%) loracarbef MICs were -32 ,ug/ml, and
thus, the strains would have been categorized as resistant.
Loracarbef resistance was not noted with strains of H.
influenzae that lacked P-lactamase. Among the cephalospo-
rins tested, cephalothin and cefaclor had essentially compa-
rable activities against H. influenzae. Both were slightly less
active than loracarbef, which was, in turn, less active than
cefuroxime. Cefixime was clearly the most active of the
cephalosporins tested against H. influenzae. As seen in
Table 3, when compared on a strain-by-strain basis, lora-
carbef MICs were typically about one twofold concentration
increment lower than the corresponding cefaclor MICs for
both ,-lactamase-positive and -negative strains of H. influ-
enzae.
TABLE 2. In vitro activities of loracarbef and other selected antimicrobial agents against H. influenzae and M. catarrhalis
Results witha:
Antimicrobial agent H. influenzae M. catarrhalis
MIC50 MIC90 MIC range 3- MIC50 MIC90 MIC range
Lactamase (pg/ml) (,ug/ml) (pug/ml) Lactamase (,ug/ml) (,g/ml) (,ug/ml)
Ampicillin + 16 32 4->32 + 2.0 4.0 0.25-4.0
- s0.25 0.5 <0.25-16 - <0.25 <0.25 <0.25
Amoxicillin-clavulanate (2:l)b + 1.0 2.0 0.5->8.0 + 0.12 0.25 <0.06-0.5
- 0.5 1.0 0.12-4.0 - <0.06 .0.06
<0.06-0.12
Cephalothin + 2.0 16 c0.5->64 + 4.0 8.0 2.0-8.0
- 2.0 8.0 .0.5-32 - <0.12 0.25
<0.12-0.25
Cefaclor + 4.0 16 1.0->32 + 1.0 2.0 s0.25-2.0
- 2.0 8.0 0.5->32 - <0.25 <0.25
.0.25
Loracarbef + 2.0 16 0.5->32 + 1.0 2.0 <0.25-4.0
- 2.0 8.0 s0.25->32 - c0.25 <0.25
s0.25
Cefuroxime + 0.5 2.0 0.5-8.0 + 1.0 2.0 0.25-4.0
- 1.0 2.0 .0.12-8.0 - 0.5 0.5
0.25-2.0
Cefixime + .0.03 0.06 s0.03->4 + 0.12 0.5 .0.03-0.5
- .0.03 0.06 .0.03-1.0 - -0.03 .0.03
.0.03-0.25
Chloramphenicol NA 1.0 2.0 .0.5-32 NA 0.5 1.0
0.5-1.0
Trimethoprim-sulfamethoxazole (1:19)c NA 0.12 0.5 .0.03-16 NA .0.12 0.5
.0.12-1.0
Erythromycin NA 4.0 8.0 .0.5-32 NA .0.5 .0.5 .0.5
Sulfisoxazole NA >64 >64 2.0->64 NA 16 >64 '0.12->64
Erythromycin-sulfisoxazole (1:64)d NA 2.0 4.0 0.12-8.0 NA <0.12 0.25 <0.12-1.0
a MIC50 and MIC90, MIC for 50 and 90% of isolates, respectively. Among the 307 strains of H. influenzae tested, 72 produced P-lactamase. Among the 146
strains of M. catarrhalis tested, 114 produced P-lactamase. NA, not available.
b Values refer to the amoxicillin concentration.
' Values refer to the trimethoprim concentration.
d Values refer to the erythromycin concentration.
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TABLE 3. Comparison of in vitro activities of loracarbef and
cefaclor against H. influenzae and M. catarrhalis
Geometric mean cefaclor MIC (p.g/ml) obtained witha:
Loracarbef MIC H. influenzae
(pLg/ml) M. catarrhalis,
Lactamase Lactamase ,-lactamase positiveb
postive negative
.32 .32 (4) .32 (2)
16 28.8 (5) 16 (10)
8.0 13.6 (10) 11.2 (20)
4.0 6.5 (8) 5.3 (32) 2.0 (2)
2.0 2.9 (30) 3.0 (75) 1.5 (24)
1.0 1.8 (13) 1.9 (84) 1.0 (75)
0.5 2.0 (2) 0.9 (12) 0.6 (22)
<0.25 <0.25 (2)
a Numbers in parentheses represent the number of strains with the indi-
cated loracarbef MIC.
b For all 32 3-lactamase-negative strains of M. catarrhalis, cefaclor and
loracarbef MICs were <0.25 ,ug/ml.
Among the other antimicrobial agents examined in this
investigation, the combination amoxicillin-clavulanate was
highly active against both 3-lactamase-positive and -negative
strains. Three strains of H. influenzae with chloramphenicol
MICs of .8.0 ,ug/ml were classified as being resistant by the
criteria of the National Committee for Clinical Laboratory
Standards (10). One strain, for which the chloramphenicol
MIC was 4.0 pg/p.l, was considered intermediate. All four of
these strains were shown to produce chloramphenicol ace-
tyltransferase. Trimethoprim-sulfamethoxazole was highly
active. MICs of .0.5/9.5 ,ug/ml were observed with 96% of
strains; these strains were thus categorized as susceptible
(10). Erythromycin and sulfisoxazole alone demonstrated
poor activity against H. influenzae; however, when com-
bined in a proportion of 1:64 (erythromycin:sulfisoxazole),
the activity of erythromycin was clearly enhanced. In gen-
eral, these observations are consistent with the results of
previous surveillance studies that have examined the prev-
alence of antibiotic resistance among clinical isolates of H.
influenzae (1, 2, 6).
Of note were 3 of 235 3-lactamase-negative strains of H.
influenzae, one each for which ampicillin MICs were 4.0,
8.0, and 16 pLg/ml, which were found to be ampicillin
resistant, even though they lacked detectable ,-lactamase.
All three of these strains were non-type b and were recov-
ered from expectorated sputum specimens from adult pa-
tients with acute purulent exacerbation of chronic bronchi-
tis. The amoxicillin-clavulanate MICs for these strains were
2.0 p.g/ml (one case) and 4.0 p.g/ml (two cases). For two of
these three ampicillin-resistant, 3-lactamase-negative strains
of H. influenzae, the loracarbef MIC was 16 p.g/ml; for the
third strain, the loracarbef MIC was 8.0 p.g/ml.
Also of interest was the observation that a much higher
percentage of isolates of H. influenzae from patients with
acute otitis media produced ,B-lactamase than did those from
patients with sinusitis or bronchopulmonary infections (Ta-
ble 1). Two previous surveillance studies in the United
States have revealed the same pattern (2, 6).
As seen in Table 2, loracarbef was also active against
clinical isolates of M. catarrhalis. Although the 3-lactamase
of M. catarrhalis appeared to influence loracarbef MICs, if
an MIC of .32 j.g/ml was used to define resistance, no
resistance was noted among either 3-lactamase-positive or
-negative strains. Among the cephalosporins tested in this
study, loracarbef was more active than cephalothin, slightly
more active than cefuroxime, essentially as active as ce-
faclor, and less active than cefixime. The equivalence of the
activities of loracarbef and cefaclor for M. catarrhalis was
apparent when MIC data were analyzed collectively (Table
2) and also when the MICs for these two agents were
compared on a strain-by-strain basis (Table 3). The high
prevalence of 3-lactamase-producing strains noted in the
current study is consistent with the results of others (6).
Among the other antimicrobial agents tested against M.
catarrhalis, resistance was noted only with ampicillin, and
then only with 3-lactamase-positive strains. As has been
described previously (4-6, 11), a large number of P-lacta-
mase-producing strains of M. catarrhalis in the present
study appeared to be susceptible to ampicillin, despite
1-lactamase production. Specifically, for 26 of 114 P-lacta-
mase-positive strains (22.8%), ampicillin MICs were <0.25
,ug/ml. It is likely that these strains produce the BRO-2- or
1908-type ,B-lactamase, as opposed to the more common
BRO-1- or Ravasio-type enzyme (11). Also of interest was
the observation that not all strains of M. catarrhalis ap-
peared to be susceptible to trimethoprim-sulfamethoxazole.
High-level resistance (i.e., MICs of >4.0/76 ,ug/ml) was not
noted. However, if the interpretive criteria of the National
Committee for Clinical Laboratory Standards for trimetho-
prim-sulfamethoxazole, when tested against H. influenzae,
were applied to M. catarrhalis, then 3% of strains tested
(i.e., 5 of 146 strains in total) would have been categorized as
having intermediate susceptibilities to trimethoprim-sulfa-
methoxazole, with MICs of 1.0/19 ,ug/ml (10).
In conclusion, the results of this study indicate that the
new orally administered carbacephem antimicrobial agent
loracarbef is at least as active as cefaclor against two
common respiratory tract pathogens, H. influenzae and M.
catarrhalis. It is likely, therefore, that loracarbef will prove
to have utility in the management of selected infections
caused by these two organisms. These include acute otitis
media, acute sinusitis, and selected bronchopulmonary in-
fections. Furthermore, the results of previous studies de-
scribing the in vitro activities of various oral antimicrobial
agents against H. influenzae and M. catarrhalis were con-
sistent with the results obtained in this investigation.
This study was supported by a grant from Eli Lilly & Co.,
Indianapolis, Ind.
The secretarial assistance of Helen Saillant was greatly appreci-
ated.
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